Raiffeisen Bank International AG Purchases Shares of 3,068 Labcorp Holdings Inc. $LH

Raiffeisen Bank International AG acquired a new position in Labcorp Holdings Inc. (NYSE:LH) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 3,068 shares of the medical research company’s stock, valued at approximately $867,000.

Other institutional investors have also recently made changes to their positions in the company. Caldwell Trust Co purchased a new stake in Labcorp during the second quarter worth $25,000. Financial Gravity Companies Inc. purchased a new position in Labcorp in the second quarter valued at $26,000. Motco acquired a new position in shares of Labcorp in the third quarter worth about $32,000. Hantz Financial Services Inc. boosted its stake in shares of Labcorp by 48.8% during the 3rd quarter. Hantz Financial Services Inc. now owns 122 shares of the medical research company’s stock worth $35,000 after acquiring an additional 40 shares in the last quarter. Finally, Headlands Technologies LLC boosted its stake in shares of Labcorp by 300.0% during the 2nd quarter. Headlands Technologies LLC now owns 128 shares of the medical research company’s stock worth $34,000 after acquiring an additional 96 shares in the last quarter. 95.94% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Labcorp

In other news, CEO Adam H. Schechter sold 5,273 shares of the company’s stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $284.38, for a total value of $1,499,535.74. Following the completion of the sale, the chief executive officer directly owned 87,343 shares in the company, valued at $24,838,602.34. This represents a 5.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Jonathan C. Meltzer sold 87 shares of the stock in a transaction that occurred on Thursday, February 12th. The shares were sold at an average price of $290.42, for a total value of $25,266.54. Following the completion of the sale, the executive vice president directly owned 2,782 shares of the company’s stock, valued at approximately $807,948.44. This represents a 3.03% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.84% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. JPMorgan Chase & Co. lifted their price target on Labcorp from $319.00 to $330.00 and gave the company an “overweight” rating in a research note on Wednesday, February 18th. Wall Street Zen upgraded Labcorp from a “hold” rating to a “buy” rating in a research report on Friday, January 23rd. Morgan Stanley reaffirmed an “overweight” rating on shares of Labcorp in a research note on Tuesday, February 17th. Robert W. Baird lifted their price target on shares of Labcorp from $313.00 to $326.00 and gave the company an “outperform” rating in a research note on Wednesday, February 18th. Finally, Weiss Ratings raised shares of Labcorp from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, February 10th. Ten analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, Labcorp has an average rating of “Moderate Buy” and an average target price of $302.75.

Labcorp Trading Up 0.0%

Shares of LH stock opened at $282.57 on Monday. Labcorp Holdings Inc. has a fifty-two week low of $209.38 and a fifty-two week high of $293.72. The firm has a market capitalization of $23.43 billion, a P/E ratio of 27.01, a PEG ratio of 1.93 and a beta of 1.03. The stock’s fifty day moving average is $265.50 and its two-hundred day moving average is $269.31. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.23 and a current ratio of 1.42.

Labcorp (NYSE:LH) last issued its earnings results on Tuesday, February 17th. The medical research company reported $4.07 EPS for the quarter, beating analysts’ consensus estimates of $3.95 by $0.12. The business had revenue of $3.52 billion during the quarter, compared to analysts’ expectations of $3.56 billion. Labcorp had a net margin of 6.28% and a return on equity of 16.16%. The company’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same period in the prior year, the business earned $3.45 earnings per share. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. Research analysts expect that Labcorp Holdings Inc. will post 16.01 earnings per share for the current fiscal year.

Labcorp Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 12th. Shareholders of record on Friday, February 27th will be paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date of this dividend is Friday, February 27th. Labcorp’s dividend payout ratio (DPR) is 27.53%.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.